Investments & Funding

The capital raised will primarily support the development of Actio’s two lead oral drug candidates: ABS-1230 and ABS-0871.

Konecta is recognized globally for its leadership in customer experience and digital services, combining human-centered solutions with advanced AI technologies.

The funding round was led by Access Biotechnology and attracted contributions from several prominent investors, including Canaan Partners, SR One, Schroders Capital, and Sanofi Ventures.

The platform leverages Keralty’s globally recognized value-based care models, which emphasize prevention, early detection, and health risk management.

Existing immunotherapies and checkpoint inhibitors have had limited success in combating this disease, highlighting the urgent need for new approaches.

This hospital complex will feature a fully equipped accident and emergency unit, oncology wards for cancer treatment, dialysis and high-dependency units for patients requiring intensive care, and a dedicated mother and child wing to improve maternal and child health outcomes.

The Greensboro plant spans 60,500 square feet (5,600 square meters) and supports both contract development and manufacturing organization (CDMO) services and packaging operations.

The new consolidated facility will have 265 beds and cover over 74,000 square meters.

Verve Therapeutics is developing innovative one-time gene editing therapies aimed at addressing the underlying causes of atherosclerotic cardiovascular disease (ASCVD).

Under the terms of the agreement, Supernus will pay US$8.50 per share in cash, amounting to an initial US$561 million for all outstanding shares of Sage.